All News

Patients with high-risk early breast cancer who received zoledronate for over 2 years did not experience an improvement in prognosis.

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.

The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.

This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.

Responses to a cross-sectional survey brought to light disparities through important aspects of diagnosing and treating brain metastases.

CancerNetwork® spoke with Quita Highsmith and Monica Baskin, MD, about the Advancing Inclusive Research Alliance and efforts to include more diverse populations in clinical trials.

Atezolizumab will no longer be available for the treatment of patients with PD-L1–positive triple-negative breast cancer following withdrawal of the indication by the agent’s developer.

Geriatric patients with prostate cancer did not experience a decline in cognative function regardless of treatment.

The phase 2 CAVE trial indicated that a combination of cetuximab and avelumab is a promising rechallenge treatment for patients with RAS wild-type metastatic colorectal cancer.

Patients with hematologic malignancies may be at a higher risk for breakthrough infections following full COVID-19 vaccination.

An oncology pharmacist speaks about the occurance of left ventricular dysfunction noted with margetuximab in the treatment of HER2-positive metastatic breast cancer.

Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.

An oncology pharmacist talks infusion-related reactions with margetuximab in the treatment of HER2-positive metastatic breast cancer.

Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.

A novel imaging technique using the folate analog tracer FA-S0456 was able to detect small, nonpalpable lung lesions otherwise undetectable by traditional means during resection surgery.

Patients with myelodysplastic syndromes showed favorable event-free survival with allogeneic stem cell transplant compared with those being treated with continuous 5-azacytidine.

Ivosidenib has received approval from the FDA for patients with IDH1-mutated cholangiocarcinoma.

Researchers utilized a ctDNA assay to evaluate minimal residual disease in patients with multiple myeloma post-autologous stem cell transplantation.

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.

Tebentafusp has demonstrated promising responses in metastatic uveal melanoma, leading to FDA and European Medicines Agency approval of a biologics license application and marketing authorization application for the agent.

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.

Patients with relapsed/refractory B-cell malignancies may potentially benefit from the combination of zandelisib and zanubrutinib.

Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.

Young-adult cancer survivors who met criteria for being prefrail and frail were more likely to experience a cognitive decline compared with those considered to be nonfrail.

The FDA issues a warning regarding the use of robotically-assisted surgical devices for mastectomy procedures related to breast cancer.

Positive preliminary data on FAP-2286 linked to the radionuclide lutetium-177 across a diverse array of adenocarcinomas was reported from the phase 1/2 LuMIERE trial.

Pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin appears to be a successful bridging regimen for patients with relapsed/refractory classical Hodgkin lymphoma.

Pfizer’s COVID-19 vaccine, Comirnaty, becomes the first fully FDA-approved vaccine against the COVID-19 virus.

Research suggests that perioperative S-1 plus oxaliplatin in patients with gastric cancer who have had a D2 gastrectomy yields a clinically significant improvement over adjuvant capecitabine plus oxaliplatin.

Priority review for a biologics license application for prophylactic abatacept has been granted by the FDA to help prevent the occurrence of severe graft-versus-host disease for patients undergoing hematopoietic stem cell transplant from an unrelated donor.